Cubist Systematic Strategies, LLC Olema Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$8.73 - $13.99 $117,121 - $187,689	13,416 New	13,416 $145,000
Q1 2023 May 15, 2023	BUY	$2.55 - $4.97 $2,654 - $5,173	1,041 Added 7.37%	15,161 $52,000
Q4 2022 Feb 14, 2023	SELL	$2.27 - $3.76 $52,650 - $87,209	-23,194 Reduced 62.16%	14,120 $34,000
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.88 $85,465 - $184,755	-31,421 Reduced 45.71%	37,314 $103,000
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.88 $85,465 - $184,755	-31,421 Reduced 45.71%	37,314 $103,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.61 $52,132 - $117,808	-25,555 Reduced 27.1%	68,735 $280,000
Q1 2022 May 16, 2022	BUY	$3.89 - $9.43 $35,367 - $85,737	9,092 Added 10.67%	94,290 $402,000
Q4 2021 Feb 14, 2022	BUY	$8.75 - $30.71 $379,452 - $1.33 Million	43,366 Added 103.67%	85,198 $797,000
Q3 2021 Nov 15, 2021	BUY	$22.96 - $30.13 $911,098 - $1.2 Million	39,682 Added 1845.67%	41,832 $1.15 Million
Q2 2021 Aug 16, 2021	BUY	$21.15 - $36.14 $45,472 - $77,701	2,150 New	2,150 $60,000

146

58.3M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $204M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.